Saka, Hideo
Kitagawa, Chiyoe
Kogure, Yoshihito
Takahashi, Yasuo
Fujikawa, Koshi
Sagawa, Tamotsu
Iwasa, Satoru
Takahashi, Naoki
Fukao, Taro
Tchinou, Catherine
Landers, Dónal
Yamada, Yasuhide
Funding for this research was provided by:
AstraZeneca
Article History
Received: 28 September 2016
Accepted: 7 December 2016
First Online: 10 January 2017
Compliance with ethical standards
:
: HS has received research funding from AstraZeneca, Daiichi Sankyo, Ono Pharmaceutical, Eli Lilly Japan, Bayer Yakuhin, Taiho Pharmaceutical, MSD, Linical, Bristol-Myers Squibb, and Sanofi. CK has received research funding from AstraZeneca and Maruishi Pharmaceutical. YK, YT, KF, TS, and NT have received research funding from AstraZeneca. SI has received research funding from AstraZeneca and honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, and Eli Lilly Japan. TF is an employee of AstraZeneca. CT and DL are employees of AstraZeneca and own AstraZeneca stock. YY has received research funding from AstraZeneca, Novartis Pharma, and Daiichi Sankyo and honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, and Yakult Pharmaceutical Industry.
: This study was funded by AstraZeneca.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.